Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-536CCB + HCTZ in Essential Hypertension
NCT02072330Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azilsartan medoxomil, amlodipine and hydrochlorothiazide in essential hypertension (5 arms), sponsored by Takeda. Primary endpoint: Change from Baseline in the office trough sitting diastolic blood pressure at 10 weeks. Started Mar 2013; status: completed.
02
Drugs
azilsartan medoxomilamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT02072330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072330.